comparemela.com

Latest Breaking News On - Irlab therapeutics - Page 2 : comparemela.com

IRLAB Announces Top-Line Results from Phase IIb Trial of Mesdopetam (IRL790) in Parkinson s disease Seite 1

17.01.2023 - GOTHENBURG, SE / ACCESSWIRE / January 17, 2023 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) a company discovering and developing novel treatments for Parkinson s disease, today announced the top-line results from the Phase IIb study of mesdopetam in . Seite 1

Top line resultsIrlab therapeutics

IRLAB reports Last Patient Last Visit ( LPLV ) Achieved in Phase IIb Clinical Study of Mesdopetam in PD-LIDs with Top-Line Results Anticipated Mid-January 2023 Seite 1

14.12.2022 - GOTHENBURG, SE / ACCESSWIRE / December 14, 2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA) Gothenburg, Sweden, December 14, 2022 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for the . Seite 1

Vastra gotalands lanRichard godfreyLast patient visitClinical studyTop line results anticipated mid januaryNasdaq stockholmNicholas watersChief executive officerIrlab therapeutics

IRLAB s partner Ipsen Initiates Clinical Studies in Line with Mesdopetam s Development Plan

06.09.2022 - GOTHENBURG, SWEDEN / ACCESSWIRE / September 6, 2022 / IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, September 6, 2022 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a clinical-stage biopharmaceutical company discovering and .

Richard godfreyIntegrative screening processIrlab therapeutics

IRLAB: Invitation to the Second Quarter and Half-year 2022 Results Presentation and Webcast

15.08.2022 - GOTHENBURG, SE / ACCESSWIRE / August 15, 2022 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)Gothenburg, Sweden, August 15, 2022 - IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a clinical-stage biopharmaceutical company discovering and developing .

Vastra gotalands lanViktor siewertzRichard godfreySecond quarterNasdaq stockholmInfront direkt studioIntegrative screening processIrlab therapeutics

IRLAB Obtains Regulatory Approval to Conduct Phase IIb Study With Pirepemat – One Step Closer To Improving Balance and Reducing Fall Injuries For People Living With Parkinson s Disease Seite 1

22.12.2021 - GOTHENBURG, SWEDEN / ACCESSWIRE / December 22, 2021 / IRLAB Therapeutics (STO:IRLAB-A) (FRA:6IRA)IRLAB (Nasdaq Stockholm: IRLAB A) IRLAB receives regulatory approval from the Swedish MPA for conducting a Phase IIb study with the investigational drug . Seite 1

Viktor siewertzJoakim tedroffIr corporate communicationsNicholas watersIrlab therapeutics

vimarsana © 2020. All Rights Reserved.